{"entity":{"id":"nct06667960","kind":"trial","name":"Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer","aka":[],"tldr":"A phase 1/2 trial of JK06 in advanced solid tumours, run by Salubris Biotherapeutics Inc, now recruiting.","summary":"Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT06667960 by Salubris Biotherapeutics Inc, with 255 participants planned, started 2024-10-23 and due to reach its primary completion in 2028-04-01. Interventions recorded: JK06.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06667960","url":"https://clinicaltrials.gov/study/NCT06667960"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06667960","phase":"1/2","setting":"A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients With Unresectable Locally Advanced or Metastatic Cancer","sponsor":"Salubris Biotherapeutics Inc","enrolled":255,"outcomes":[]},"route":"/trials/nct06667960/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}